Abstract
High-dose interleukin-2 (IL-2) is an available treatment option for patients with metastatic melanoma or renal cell carcinoma, and is associated with sustained complete and partial responses in a subset of patients. IL-2, however, is not devoid of toxicities, most of which involve the cardiovascular system and manifest as hypotension, arrhythmias, and cardiomyopathy. This report describes an unusual presentation of takotsubo cardiomyopathy in a postmenopausal woman receiving high-dose IL-2 for metastatic melanoma.
Cite
CITATION STYLE
Damodaran, S., Mrozek, E., Liebner, D., & Kendra, K. (2014). Focal takotsubo cardiomyopathy with high-dose interleukin-2 therapy for malignant melanoma. JNCCN Journal of the National Comprehensive Cancer Network, 12(12), 1666–1670. https://doi.org/10.6004/jnccn.2014.0168
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.